Tag archief: English Only

H.I.G. Capital Raises $1.3 Billion for Infrastructure Fund

MIAMI–(BUSINESS WIRE)– H.I.G. Capital (“H.I.G.” or “the Firm”), a leading global alternative asset management firm with $64 billion of capital under management, is pleased to...

Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology

News summary: As cyber threats to GNSS grow, network operators are turning to alternative sources of positioning, navigation and timing data Adtran’s Oscilloquartz solutions now...

New Report Exposes the “Dark Underworld” of Illegal Tobacco Trade in Canada, France, the Philippines and the United Kingdom

Buying illegal tobacco products is in danger of becoming normalized, with 43% of adult smokers surveyed comfortable buying cigarettes, even if they know they are...

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common and...

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161 Mezagitamab Had a...

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for...

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions

– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day...

Slate Asset Management Completes Approximately €425 Million of Senior Debt Refinancings for Its European Essential Real Estate Portfolio Year to Date

LONDON–(BUSINESS WIRE)– Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has completed approximately €425 million of senior...

ASTRA 1P Successfully Launched on SpaceX’s Falcon 9 Rocket

Most powerful geostationary satellite to operate at 19.2 degrees East will deliver content from SES’s prime TV neighbourhood to 119 million households across Europe CAPE...

Independent Survey of Nearly 3,000 Global CFOs and CIOs Reveals Growing Demand for Results and ROI from IT Investments and Decisions

To solve for rising IT costs, IT and finance leaders collaborate to scrutinize technology spend and ensure budgetary and business goals are met LAS VEGAS–(BUSINESS...

TDC NET Upgrades Optical Transport Network to 800G with Ciena

New network based on Ciena WaveLogic 5 technology enables TDC NET to bring new services to market in a sustainable and secure way HANOVER, Md.–(BUSINESS...

Adtran joins LU-CIX community as a Gold Member

News summary: LU-CIX member ecosystem enhances Luxembourg’s digital infrastructure through strategic alliances and technological innovation Adtran’s membership reinforces a longstanding collaboration, with its open FSP...

Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI®

 – Agreement includes access to any future licence extensions – LONDON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an extended long-term reimbursement agreement with...

SES Announces Successful Syndication and Raising of €3 Billion Acquisition Financing

€2.1 billion bridge facility provided by a group of relationship banks US$1 billion bank term loan facility to cover part of the financing requirements Extension...

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

The Swedish Medical Products Agency has issued a license update authorizing the future manufacture and bioanalytical testing of Galderma’s proprietary investigational ready-to-use liquid botulinum toxin...